NCT00344526View on ClinicalTrials.gov

Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2000

Study Completion Date

June 30, 2006

Conditions
Primary Systemic Amyloidosis (AL)
Interventions
DRUG

Melphalan

DRUG

Dexamethasone

PROCEDURE

Autologous stem cell transplantation

Trial Locations (8)

Unknown

Service des Maladies du Sang, Lille

Service d'Hématologie et de Thérapie cellulaire, Limoges

Service d'hématologie clinique, Nantes

Service d'hématologie Clinique, Groupe Hospitalier Pitié-Salpétrière, Paris

Service d'hématologie clinique, Hôpital Necker, Paris

Service d'immuno-hématologie, Hôpital Saint-Louis, Paris

Service d'hématologie, Toulouse

Hématologie Clinique, Tours

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

University Hospital, Limoges

OTHER

NCT00344526 - Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | Biotech Hunter | Biotech Hunter